Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Human Papillomavirus
Scientists at University of Turin publish research in human papillomavirus
May 20th, 2008
Scientists discuss in 'Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus' new findings in human papillomavirus. "Genital human papillomaviruses (HPV) represent the most common sexually transmitted agents and are classified into low or high risk by their propensity to cause genital warts or cervical cancer, respectively. Topical microbicides against HPV may be a useful adjunct to the newly licensed HPV vaccine," scientists writing in the journal Antimicrobial Agents and Chemotherapy report. "A main objective in the development of novel microbicides is to block HPV entry into epithelial cells...
Source: Cancer Weekly (2008-05-20)
|
